Journal Article

Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial

McHugo, Maureen, Rogers, Baxter, Avery, Suzanne, Armstrong, Kristan, Donahue, Manus, Heckers, Stephan, Roeske, Maxwell J.

2024

Overview

Hippocampal hyperactivity is a novel pharmacological target in the treatment of schizophrenia. We hypothesized that levetiracetam (LEV), a drug binding to the synaptic vesicle glycoprotein 2 A, normalizes hippocampal activity in persons with schizophrenia and can be measured using neuroimaging methods. Thirty healthy control participants and 30 patients with schizophrenia (28 treated with antipsychotic drugs), were randomly assigned to a double-blind, cross-over trial to receive a single administration of 500 mg oral LEV or placebo during two study visits. At each visit, we assessed hippocampal function using resting state fractional amplitude of low frequency fluctuations (fALFF), cerebral blood flow (CBF) with arterial spin labeling, and hippocampal blood-oxygen-level-dependent (BOLD) signal during a scene processing task. After placebo treatment, we found significant elevations in hippocampal fALFF in patients with schizophrenia, consistent with hippocampal hyperactivity. Additionally, hippocampal fALFF in patients with schizophrenia after LEV treatment did not significantly differ from healthy control participants receiving placebo, suggesting that LEV may normalize hippocampal hyperactivity. In contrast to our fALFF findings, we did not detect significant group differences or an effect of LEV treatment on hippocampal CBF. In the context of no significant group difference in BOLD signal, we found that hippocampal recruitment during scene processing is enhanced by LEV more significantly in schizophrenia. We conclude that pharmacological modulation of hippocampal hyperactivity in schizophrenia can be studied with some neuroimaging methods, but not others. Additional studies in different cohorts, employing alternate neuroimaging methods and study designs, are needed to establish levetiracetam as a treatment for schizophrenia.

• Publisher: Nature Publishing Group,Springer International Publishing
• Subject: Anticonvulsants - therapeutic use / Antipsychotics / Blood flow / Blood levels / Cerebral blood flow / Double-Blind Method / Etiracetam / Functional magnetic resonance imaging / Hippocampus / Hippocampus - diagnostic imaging / Humans / Hyperactivity / Levetiracetam / Medical imaging / Mental disorders / Neuroimaging / Piracetam - adverse effects / Piracetam - therapeutic use / Placebos / Schizophrenia / Schizophrenia - chemically induced / Schizophrenia - diagnostic imaging / Schizophrenia - drug therapy / Spin labeling